Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pristinamycin→

Pristinamycin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
270076-60-3
Molecular formula
C71H84N10O17
Molecular weight
1349.5 g/mol
Drug class
Streptogramin antibacterial combinationprotein-synthesis inhibitor
Mechanism of action
Contains synergistic streptogramin components that bind distinct sites on the 50S ribosomal subunit, inhibiting peptide-chain elongation and producing bactericidal activity against susceptible Gram-positive bacteria.
Indications / reported uses
  • Treatment of selected skin, soft-tissue and respiratory infections caused by susceptible Gram-positive bacteria, including certain resistant staphylococci, in countries where pristinamycin is authorised; current availability and antimicrobial susceptibility must be checked

Sources: NLM MeSH — Pristinamycin · PubMed — Pristinamycin streptogramin mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pristinamycin Environmental Risk Assessment (ERA) (the Pristinamycin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.